CAR-T (chimeric antigen receptor T cell) therapy spent its first decade as a cancer treatment — initially for B-cell leukemia, then lymphoma, then multiple myeloma. The premise was simple: engineer a patient's own T cells to recognize and kill cells bearing a specific surface marker (CD19, BCMA), then infuse billions of these engineered soldiers back to hunt down and destroy the cancer. It worked, producing durable complete remissions in patients who had failed every prior therapy.
In 2021, Georg Schett's team at the University of Erlangen had a hypothesis: what if the same approach could eliminate the autoreactive B cells responsible for driving systemic lupus erythematosus? The B cells that produce anti-dsDNA antibodies, anti-Sm antibodies, and the complement-fixing immune complexes that destroy kidneys, joints, and brain? In 2026, the answer is clear — and it has transformed the outlook for patients with the most severe autoimmune diseases.
The Erlangen Experience: Five Years of Follow-Up
The Erlangen group's landmark case series, originally published in Nature Medicine in 2021 with 5 patients, has now expanded to 27 patients with severe, refractory SLE who failed ≥3 prior immunosuppressive regimens including hydroxychloroquine, mycophenolate, belimumab, and anifrolumab. Five-year follow-up of the initial cohort was published in NEJM in March 2026:
- Complete clinical remission (SLEDAI-2K = 0, no immunosuppression): 18 of 27 patients (67%) at median 36-month follow-up
- Autoantibody elimination: Anti-dsDNA antibodies became undetectable within 3 months in 23 of 27 patients and remain undetectable in 19 at last follow-up
- Renal function: Proteinuria resolved in all 6 patients who had active lupus nephritis at baseline
- B cell reconstitution: Naive B cells (not autoreactive) reconstituted from hematopoietic stem cells by Month 12 in all patients — the autoreactive B cell clones that drove disease did not return
- Drug-free remission: 14 patients remain off all immunosuppression (including hydroxychloroquine) for a median of 28 months
Expansion to Other Autoimmune Diseases
The Erlangen approach has now been applied to a broader range of severe autoimmune conditions in multicenter trials:
- Systemic sclerosis (scleroderma): Phase II trial of 18 patients; improved skin score (mRSS) by 41% at 12 months; no disease worsening
- Idiopathic inflammatory myopathies (dermatomyositis, anti-synthetase syndrome): Case series of 11 patients; 8 achieved clinical remission; 3 with interstitial lung disease showed stable or improving PFTs
- Anti-NMDA receptor encephalitis: 4 cases with refractory disease; all achieved neurological stabilization or improvement
- ANCA vasculitis: Phase I/II trial enrolling; no results yet available
Manufacturing and Access: The Central Challenge
Autologous CAR-T manufacturing — extracting T cells from the patient, engineering them, expanding them in culture, and reinfusing — takes 3–5 weeks and costs $400,000–$600,000 per patient. For cancer, where the alternative is death, this cost is justifiable. For autoimmune disease, where patients are chronically ill but usually survive long term, the cost-effectiveness equation is more complex.
Allogeneic ("off-the-shelf") CAR-T, manufactured from healthy donor cells, could eliminate manufacturing delay and reduce cost to one-tenth of autologous. Several allogeneic anti-CD19 CAR-T products are in Phase I trials for SLE in 2026, with preliminary data expected in late 2026.
What This Means for Rheumatology Practice
CAR-T is not going to replace hydroxychloroquine for well-controlled lupus. But for the 5–10% of SLE patients whose disease is refractory to multiple biologic agents, causes organ-threatening nephritis or neuropsychiatric involvement, or requires chronic high-dose corticosteroids causing their own damage, a one-time curative intervention is transformative. Rheumatology practices are beginning to develop CAR-T referral pathways in partnership with academic hematology centers.
Conclusion
CAR-T cell therapy for autoimmune disease is among the most exciting developments in medicine of the past five years. The biology is compelling: deplete the autoreactive B cell clones driving disease, allow immune reconstitution from naive precursors, and the disease disappears. The early clinical data suggests this works, durably, in the most severe and refractory patients. Scaling it to accessibility remains the defining challenge of the coming decade. Healthcare facilities can find relevant diagnostic equipment in our catalog.
